China's vaccine developers stuck with unused mRNA COVID-19 shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue.
Three Chinese companies — Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics — came up with mRNA vaccines that won limited emergency approvals in Asia.
However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official said.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.